Fluoguide announce green light to proceed to the third dose level in the ongoing ph I/II trial in patients with high grade glioma. The results from the second dose level are in line with data from the first dose level in respect to safety and tolerability and lights was detected in 100% of patients. The data provide further validation of FG001 mode-of-action but we will await the complete dataset from the dose-escalation phase of the trial before further de-risking the case.
LÄS MER
